Telo Genomics Corp's shares have seen a notable decline this week, reflecting broader market trends in the health care sector.
Telo Genomics Corp (TELO.V) has had a tough week, with its stock price dropping 12.50% over the past five trading days. As of the latest close, the stock is trading at C$0.04, marking a significant decrease of 30% year-to-date. Despite the lack of major company news to explain this movement, investors are closely monitoring the stock's technical indicators and trading volume.
Advertisement
Telo Genomics Corp
TELO.V
TELO.V
Telo Genomics Corp
WealthAwesomeMarket cap
$3.52M
52W high
$0.10
52W low
$0.04
1W change
-12.50%
Beta
0.17
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELO's historical volatility
30-Day Vol
144.4%
Annualized
90-Day Vol
127.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.03
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.03 | C$0.02 – C$0.05 |
| 60 trading days | C$0.03 | C$0.02 – C$0.06 |
| 90 trading days | C$0.03 | C$0.01 – C$0.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While Telo Genomics has faced a turbulent week, investors should consider the stock's technical indicators and historical performance before making any decisions. The low trading volume compared to its average may suggest a lack of strong investor interest at this time.
C$0.04 Close, 12.50% Weekly Decline
With a market cap of approximately C$3.5 million and a 52-week trading range of C$0.04 to C$0.10, Telo Genomics remains at a critical juncture.
Bull case
Investors who believe in Telo Genomics’ long-term potential might see the current price as a chance to buy in at a lower valuation, especially if the company can improve its financial metrics in the future.
Bear case
On the other hand, the significant drop in stock price and the company's poor financial health, including a negative return on equity and a profit margin of 0.0%, may discourage potential investors and indicate ongoing challenges for Telo Genomics.
Price Action Overview
Advertisement
Telo Genomics Corp's stock closed at C$0.04 on Friday, showing no change from the previous day. The stock has struggled this week, down 12.50% over the last five trading days. Year-to-date, it has declined by 30%, reflecting broader concerns in the health care sector.
Technical Picture
The technical indicators for Telo Genomics reveal a challenging outlook. The stock is currently trading below both its 50-day moving average (C$0.04) and its 200-day moving average (C$0.05), indicating bearish momentum. The stock has a 52-week range of C$0.04 to C$0.10, and it is currently at the lower end of this range. The beta of 0.17 indicates lower volatility compared to the market, but the recent trading volume of 11,000 shares is significantly below the 20-day average of 78,987 shares, suggesting a lack of investor engagement.
Fundamental Insights
Telo Genomics has a market capitalization of approximately C$3.5 million, with a profit margin of 0.0% and a return on equity of -3055.8%. The negative earnings per share (EPS) of -0.03 indicates ongoing financial struggles. Investors may need to consider these fundamental factors when assessing the stock's potential for recovery or further decline.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
